Active — Not RecruitingNot Applicable

Women at Risk of Breast Cancer and OLFM4

France150 participantsStarted 2016-03-08

Plain-language summary

Does the olfactomédine provide an help to limit the number of false positives in the overall imaging balance and limit the number of unnecessary biopsies?

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age \> or = 18 years * High risk women of breast cancer occurrence defined by the following criteria: * Women carrying a genetic mutation BRCA1 or 2 or TP53, entering or already in screening breast IRM * Women with a high probability of hereditary predisposition to breast cancer (20% risk at 70 years of breast cancer by BOADICEA model), assessed by the onco-geneticists * Information of the person and signing the informed consent Exclusion Criteria: * Women with a history of breast cancer or in situ * Person who is not affiliated to a social security scheme or beneficiary of such a regime

What they're measuring

Predictive value of circulating OLFM4 in BRCA1/2 mutation carriers or high-risk women with positive breast imaging

Timeframe: Every 6 months, up to 10 years (120 months)

Trial details

NCT IDNCT02653105

SponsorInstitut Cancerologie de l'Ouest

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-03

View on ClinicalTrials.gov More Hereditary Breast and Ovarian Cancer Syndrome trials